Drug Sponsors

Marina Biotech to close Cambridge site

Thursday, February 16, 2012 06:33 AM

Marina Biotech, a nucleic acid-based drug discovery and development company, will be closing its Cambridge, Mass., site and consolidating all R&D efforts at its headquarters in Bothell, Wash.

More... »

Valeant to acquire Eyetech

Wednesday, February 15, 2012 03:45 PM

Valeant Pharmaceuticals International has agreed to acquire Eyetech, a privately-owned ophthalmic biotechnology company, for an undisclosed upfront payment and potential future milestones.

More... »

Biogen Idec acquires Stromedix for $75 million

Wednesday, February 15, 2012 03:01 PM

Biogen Idec has aqcuired Stromedix, a privately held biotechnology company focused on therapies for fibrosis and organ failure, for $75 million cash.

More... »

Linden Capital Partners to acquire SeraCare for $82 million

Monday, February 13, 2012 03:08 PM

SeraCare Life Sciences, a global life sciences company, has agreed to be acquired by an affiliate of Linden Capital Partners, a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare and life science industries.

More... »

GSK expands Australian facility, creates 58 jobs

Friday, February 10, 2012 02:05 PM

GlaxoSmithKline (GSK) is investing roughly $64 million to expand its manufacturing and drug development activities in its Boronia facility near Melbourne, Australia.

More... »

Takeda establishes development center in China

Friday, February 10, 2012 09:54 AM

Takeda Pharmaceutical has established the Takeda Shanghai Development Center ("TSDC") within the Shanghai-based Takeda (China) Holdings (TCH), a wholly owned subsidiary of Takeda.

More... »

Illumina’s board unanimously rejects Roche’s offer

Wednesday, February 8, 2012 12:52 PM

Illumina’s board of directors has thoroughly reviewed Roche’s unsolicited tender offer with the assistance of its financial and legal advisors and, according to the company, has unanimously determined that the $44.50 per share cash offer is grossly inadequate in multiple respects, dramatically undervalues Illumina and is contrary to the best interests of Illumina’s stockholders.

More... »

Boehringer Ingelheim, GWT and TU Dresden sign diabetes research collaboration

Tuesday, February 7, 2012 11:14 AM

Boehringer Ingelheim, GWT and the Department of Medicine of the TU Dresden have signed a research collaboration agreement to develop new insights into the causes of diabetes and the link between excessive blood glucose, the hallmark of diabetes, and the serious complications of the disease that can affect many organ functions.

More... »

Pfizer recalls birth control due to out of order tablets

Monday, February 6, 2012 01:56 PM

Pfizer has voluntarily recalled 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 lots of Norgestrel and Ethinyl Estradiol tablets (generic) on the U.S. market—approximately 1 million packs.

More... »

Threshold, Merck to collaborate

Monday, February 6, 2012 01:51 PM

Threshold Pharmaceuticals has signed a global agreement with Germany-based Merck to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

More... »